Resistance to β-lactam antibiotics in bacteroides spp.

Journal of Medical Microbiology

Volumn 46, Issue 12, 1997, Pages 979-986

  Edwards, R ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEROIDES; BACTEROIDES FRAGILIS; DRUG PENETRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL;

EID: 0030834579     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-46-12-979     Document Type: Article

References (101)

1. Veillon A, Zuber A. Recherches sur quelques microbes strictement anaérobies et leur rôle en pathologie. Arch Méd Exper Anat Path 1898; 10: 517-545.
2. Finegold SM. Pathogenic anaerobes. Arch Intern Med 1982; 142: 1988-1992.
3. Hedberg M, Nord CE. Antimicrobial-resistant anaerobic bacteria in human infections. Med Microbiol Lett 1996; 5: 295-304.
4. McGowan K, Gorbach SL. Anaerobes in mixed infections. J Infect Dis 1981; 144: 181-186.
5. Namavar F, Theunissen EBM, Verweij-Van Vught AMJJ et al. Epidemiology of the Bacteroides fragilis group in the colonic flora in 10 patients with colonic cancer. J Med Microbiol 1989; 29: 171-176.
6. Finegold SM. Anaerobic infections in humans: an overview. Anaerobe 1995; 1: 3-9.
7. Gorbach SL, Bartlett JG. Medical progress: anaerobic infections. 1. N Engl J Med 1974; 290: 1177-1184.
8. Thadepalli H, Gorbach SL, Keith L. Anaerobic infections of the female genital tract - bacteriologic and therapeutic aspects. Am J Obstet Gynecol 1973; 117: 1034-1040.
9. Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. Am Rev Respir Dis 1974; 110: 56-77.
10. Ingham HR, Selkon JB, Roxby CM. Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole. BMJ 1977; 2: 991-993.
11. Louie TJ, Bartlett JG, Tally FP, Gorbach SL. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med 1976; 85: 461-463.
12. Spencer RC. Anaerobic bacteraemia. In: Duerden BI, Draser BS (eds) Anaerobes in human disease. London, Edward Arnold. 1991: 324-342.
13. Rasmussen BA, Bush K, Tally FP. Antibiotic resistance in Bacteroides. Clin Infect Dis 1993; 16 Suppl 4: S390-S400.
14. Wexler HM, Finegold SM. Antimicrobial resistance in Bacteroides. J Antimicrob Chemother 1987; 19: 143-146.
15. Sutter VL, Finegold SM. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother 1976; 10: 736-752.
16. Rolfe RD, Finegold SM. Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother 1981; 20: 600-609.
17. Clarke AM, Zemcov SJ. Comparative in-vitro activity of temocillin (BRL 17421), a new penicillin. J Antimicrob Chemother 1983; 11: 319-324.
18. Cuchural GJ, Tally FP, Jacobus NV et al. Comparative activities of newer β-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother 1990; 34: 479-480.
19. Jacobs MR, Spangler SK, Appelbaum PC. Beta-lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents. Eur J Clin Microbiol Infect Dis 1992; 11; 1081-1093.
20. Olsson-Liljequist B, Dornbusch K, Nord CE. Characterization of three different β-lactamases from the Bacteroides fragilis group. Antimicrob Agents Chemother 1980; 18: 220-225.
21. Cuchural GJ, Tally FP, Jacobus NV, Marsh PK, Mayhew JW. Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother 1983; 24: 936-940.
22. Phillips I, King A, Nord CE, Hoffstedt B. Antibiotic sensitivity of the Bacteroides fragilis group in Europe. European Study Group. Eur J Clin Microbiol Infect Dis 1992; 11: 292-304.
23. Jacobus NV, Curchural GJ, Tally FP. In-vitro susceptibility of the Bacteroides fragilis group and the inoculum effect of the newer β-lactam antibiotics on this group of organisms. J Antimicrob Chemother 1989; 24: 675-682.
24. Betriu C, Campos E, Cabronero C, Rodriguez-Avial C, Picazo JJ. Susceptibilities of species of the Bacteroides fragilis group to 10 antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 671-673.
25. Martin DA, Saunders CV, Marier RL. N-formimidoyl thienamycin (MK 0787): in vitro activity against anaerobic bacteria. Antimicrob Agents Chemother 1982; 21: 168-169.
26. Edwards JR, Turner PJ, Wannop C, Withnell EW, Grindey AJ, Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother 1989; 33: 215-222.
27. Aldridge KE, Morice N, Schiro DD. In vitro activity of Biopenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994; 38: 889-893.
28. Betriu C, Cabronero C, Gomez M, Picazo JJ. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989. Eur J Clin Microbiol Infect Dis 1992; 11: 352-356.
29. Goldstein EJC, Citron DM, Cherubin CE, Hillier SL. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993; 31: 363-372.
30. Edwards R, Thirlwell D, Greenwood D. Changes in β-lactam antibiotic susceptibility and β-lactamase production of clinical isolates of Bacteroides and Prevotella species over a 9 year period. J Antimicrob Chemother 1996; 37: 636-638.
31. Diedrich DL, Martin AE. Outer membrane proteins of Bacteroides fragilis group. Curr Microbiol 1981; 6: 85-88.
32. Kotarski SF, Salyers AA. Isolation and characterization of outer membranes of Bacteroides thetaiotaomicron grown on different carbohydrates. J Bacteriol 1984; 158: 102-109.
33. Wexler HM, Getty C, Fisher G. The isolation and characterisation of a major outer-membrane protein from Bacteroides distasonis. J Med Microbiol 1992; 37: 165-175.
34. Wexler HM, Getty C. The isolation and characterisation of a porin protein from Bacteroides fragilis. Anaerobe 1996; 2: 305-312.
35. Kanazawa K, Kobayshi Y, Nakano M, Sakurai M, Gotoh N, Nishino T. Identification of three porins in the outer membrane of Bacteroides fragilis. FEMS Microbiol Lett 1995; 127: 181-186.
36. Yoshimura F, Nikaido H. Diffusion of β-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother 1985; 27: 84-92.
37. Curchural GJ, Hurlbut S, Malamy MH, Tally FP. Permeability to β-lactams in Bacteroides fragilis. J Antimicrob Chemother 1988; 22: 785-790.
38. Hiruma R, Yamaguchi A, Sawai T. The effect of lipopolysaccharide on lipid bilayer permeability of β-lactam antibiotics. FEBS Lett 1984; 170: 268-272.
39. Edwards R, Greenwood D. Outer membrane analysis of B. fragilis strains with reduced susceptibility to imipenem. In: Duerden BI, Wade WG, Brazier JS, Wren WG, Hudson MJ (eds) Medical and dental aspects of anaerobes. Northwood Middlesex, Science Reviews. 1993: 307-309.
40. Dornbusch K, Olsson-Liljequist B, Nord CE. Antibacterial activity of new β-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis. J Antimicrob Chemother 1980; 6: 207-216.
41. Olsson B, Dornbusch K, Nord CE. Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis. Antimicrob Agents Chemother 1979; 15: 263-268.
42. Cuchural GJ, Malamy MH, Tally FP. β-Lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother 1986; 30: 645-648.
43. Crosby MA, Gump DW. Activity of cefoperazone and two β-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with β-lactamase production. Antimicrob Agents Chemother 1982; 22: 398-405.
44. Malouin F. Lamothe F. The role of β-lactamases and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group. Can J Microbiol 1987; 33: 262-266.
45. Piddock LJ, Wise R. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility. J Antimicrob Chemother 1987; 19: 161-170.
46. Iaconis JP, Nadler HL, Sheikh W. Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates. Clin Infect Dis 1995; 20 Suppl 2: S361-S363.
47. Nord CE, Hedberg M. Resistance to β-lactam antibiotics in anaerobic bacteria. Rev Infect Dis 1990; 12 Suppl 2: S231-S234.
48. Garrod LP. Sensitivity of four species of Bacteroides to antibiotics. BMJ 1955; ii: 1529-1531.
49. Pinkus G, Veto G, Braude AI. Bacteroides penicillinase. J Bacteriol 1968; 96: 1437-1438.
50. Olsson B, Dornbusch K, Nord CE. Susceptibility to beta-lactam antibiotics and production of beta-lactamases in Bacteroides fragilis. Med Microbiol Immunol 1977; 163: 183-194.
51. Dias MBS, Jacobus NV, Tally FP. In-vitro activity of cefoperazone-sulbactam against Bacteroides species. J Antimicrob Chemother 1986; 18: 467-471.
52. Cornick NA, Cuchural GJ, Snydman DR et al. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother 1990; 25: 1011-1019.
53. Rogers MB, Bennett TK, Payne CM, Smith CJ. Insertional activation of cepA leads to high-level beta-lactamase expression in Bacteroides fragilis clinical isolates. J Bacteriol 1994; 176: 4376-4384.
54. Anderson JD, Sykes RB. Characterisation of a β-lactamase obtained from a strain of Bacteroides fragilis resistant to β-lactam antibiotics. J Med Microbiol 1973; 6: 201-206.
55. Olsson B, Nord C-E, Wadstrom T. Formation of β-lactamase in Bacteroides fragilis: cell-bound and extracellular activity. Antimicrob Agents Chemother 1976; 9: 727-735.
56. Wise R. Clavulanic acid and susceptibility of Bacteroides fragilis to penicillin. Lancet 1977; 2: 145.
57. Britz ML, Wilkinson RG. Purification and properties of a beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother 1978; 13: 373-382.
58. Brown JE, Del Bene VE, Collins CD. In vitro activity of N-formimidoyl thienamycin, moxalactam and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrob Agents Chemother 1981; 19: 248-252.
59. Timewell R, Taylor E, Phillips I. The β-lactamases of Bacteroides species. J Antimicrob Chemother 1981; 7: 137-146.
60. Tajima M, Sawa K, Watanabe K, Ueno K. The β-lactamases of genus Bacteroides. J Antibiot 1983; 36: 423-428.
61. Richmond MH, Sykes RB. The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973; 9: 31-88.
62. Neu HC. Antibiotic inactivating enzymes and bacterial resistance. In: Lorian V (ed) Antibiotics in laboratory medicine. Baltimore, Williams and Wilkins. 1986: 757-789.
63. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
64. Rogers MB, Parker AC, Smith CJ. Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler Class A β-lactamases. Antimicrob Agents Chemother 1993; 37: 2391-2400.
65. Ambler RP. The structure of β-lactamases. Philos Trans R Soc London B. Biol Sci 1980; 289: 321-331.
66. Parker AC, Smith CJ. Genetic and biochemical analysis of a novel ambler class A β-lactamase responsible for cefoxitin resistance in Bacteroides species. Antimicrob Agents Chemother 1993; 37: 1028-1036.
67. Smith CJ, Bennett TK, Parker AC. Molecular and genetic analysis of the Bacteroides uniformis cephalosporinase gene, cblA, encoding the species-specific β-lactamases. Antimicrob Agents Chemother 1994; 38: 1711-1715.
68. Hedberg M, Lindqvist L, Bergman T, Nord CE. Purification and characterization of a new β-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother 1995; 39: 1458-1461.
69. Sato K, Matsuura Y, Inoue M, Mitsuhashi S. Properties of a new pencillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother 1982; 22: 579-584.
70. Yang Y, Rasmussen BA, Bush K. Biochemical characterization of the metallo-β-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother 1992; 36: 1155-1157.
71. Ajiki Y, Koga T, Ohya S et al. β-Lactamase produced by a highly β-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections. J Antimicrob Chemother 1991; 28: 537-546.
72. Bandoh K, Muto Y, Watanabe K, Katoh N, Ueno K. Biochemical properties and purification of metallo-β-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother 1991; 35: 371-372.
73. Hedberg M, Edlund C, Lindqvist L, Rylander M, Nord CE. Purification and characterization of an imipenem hydrolysing metallo-β-lactamase from Bacteroides fragilis. J Antimicrob Chemother 1992; 29: 105-113.
74. Livermore DM. Carbapenemases: the next generation of β-lactamases? ASM News 1993; 59: 129-134.
75. Livermore DM. Carbapenemases. J Antimicrob Chemother 1992; 29: 609-612.
76. Eley A, Greenwood D. Characterization of β-lactamases in clinical isolates of Bacteroides. J Antimicrob Chemother 1986; 18: 325-333.
77. Edwards R, Greenwood D. An investigation of β-lactamases from clinical isolates of Bacteroides species. J Med Microbiol 1992; 36: 89-95.
78. Rasmussen BA, Gluzman Y, Tally FP. Cloning and sequencing of the class B β-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother 1990; 34: 1590-1592.
79. Thompson JS, Malamy NH. Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus β-lactamase II. J Bacteriol 1990; 172: 2584-2593.
80. Rasmussen BA, Gluzman Y, Tally FP. Escherichia coli chromosomal mutations that permit direct cloning of the Bacteroides fragilis metallo-β-lactamase gene, ccrA. Mol Microbiol 1991; 5: 1211-1219.
81. Podglajen I, Breuil J, Bordon F, Gutmann L, Collatz E. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol Lett 1992; 91: 21-30.
82. Rasmussen BA, Yang Y, Jacobus N, Bush K. Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of β-lactams in three Bacteroides fragilis isolates that harbor a metallo-β-lactamase gene. Antimicrob Agents Chemother 1994; 38: 2116-2120.
83. Podglajen I, Breuil J, Coutrot A, Gutmann L, Collatz E. Incidence of the carbapenem (Cpm) resistance gene cfiA and variability of its genomic environment in Cpm-resistant and -susceptible clinical isolates of Bacteroides fragilis. In: Abstracts of the 32nd Interscienee Conference on Antimicrobial Agents and Chemotherapy, 1992. Abstract 583: 208.
84. Podglejen I, Breul J, Collatz E. Insertion of a novel DNA sequence, IS1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis. Mol Microbiol 1994; 12: 105-114.
85. Turner P, Edwards R, Weston V, Gazis A, Ispahani P, Greenwood D. Simultaneous resistance to metronidazole, coamoxiclav, and imipenem in a clinical isolate of Bacteroides fragilis. Lancet 1995; 345: 1275-1277.
86. Khushi T, Payne DJ, Fosberry A, Reading C. Production of metal dependent β-lactamases by clinical strains of Bacteroides fragilis isolated before 1987. J Antimicrob Chemother 1996; 37: 345-350.
87. Podglajen I, Breuil J, Casin I, Collatz E. Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content. J Bacteriol 1995; 177: 5270-5275.
88. Yotsuji A, Minami S, Inoue M, Mitsuhashi S. Properties of novel β-lactamase produced by Bacteroides fragilis. Antimicrob Agents Chemother 1983; 24: 925-929.
89. Hurlbut S, Cuchural GJ, Tally FP. Imipenem resistance in Bacteroides distasonis mediated by a novel β-lactamase. Antimicrob Agents Chemother 1990; 34: 117-120.
90. Cuchural GJ, Tally FP, Storey JR, Malamy MH. Transfer of β-lactamase-associated cefoxitin resistance in Bacteroides fragilis. Antimicrob Agents Chemother 1986; 29: 918-920.
91. Rashtchian A, Dubes GR, Booth SJ. Transferable resistance to cefoxitin in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 1982; 22: 701-703.
92. Bandoh K, Watanabe K, Muto Y, Tanaka Y, Kato N, Ueno K. Conjugal transfer of imipenem resistance in Bacteroides fragilis. J Antibiot 1992; 45: 542-547.
93. Malouin F, Bryan LE. Modification, of penicillin-binding proteins as mechanisms of β-lactam resistance. Antimicrob Agents Chemother 1986; 30: 1-5.
94. Georgopapadakou NH, Smith SA, Sykes RB. Mode of action of aztreonam. Antimicrob Agents Chemother 1982; 21: 950-956.
95. Piddock LJ, Wise R. Properties of pencillin-binding proteins of four species of the genus Bacteroides. Antimicrob Agents Chemother 1986; 29: 825-832.
96. Wexler HM, Halebian S. Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-β-lactamase mediated cefoxitin resistance. J Antimicrob Chemother 1990; 26: 7-20.
97. Botta GA, Privitera G, Menozzi MG. Penicillin-binding proteins in Bacteroides fragilis and their affinities for several new cephalosporins. J Antimicrob Chemother 1983; 11: 325-331.
98. Georgopapadakou NH, Smith SA, Sykes RB. Penicillin-binding proteins in Bacteroides fragilis. J Antibiot 1983; 36: 907-910.
99. Yotsuji A, Mitsuyama J, Hori R et al. Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother 1988; 32: 1848-1853.
100. Edwards R, Greenwood D. Mechanisms responsible for reduced susceptibility to imipenem in Bacteroides fragilis. J Antimicrob Chemother 1996; 38: 941-951.
101. Hedberg M, Bush K, Bradford PA et al. The role of penicillin-binding-proteins for β-lactam resistance in a β-lactamase producing Bacteroides uniformis strain. Anaerobe 1996; 2: 111-115.